Mastura Monif, Richard P Sequeira, Andrea Muscat, Sian Stuckey, Paul G Sanfilippo, Viet Minh, Naomi Loftus, Veronica Voo, Katherine Fazzolari, Melinda Moss, Vicki E Maltby, Ai-Lan Nguyen, Robb Wesselingh, Nabil Seery, Cassie Nesbitt, Josephine Baker, Chris Dwyer, Lisa Taylor, Louise Rath, Anneke Van der Walt, Mark Marriott, Tomas Kalincik, Jeannette Lechner-Scott, Terence J O'Brien, Helmut Butzkueven
Cladribine (Mavenclad®) is an oral treatment for relapsing remitting MS (RRMS), but its mechanism of action and its effects on innate immune responses in unknown. This study is a prospective Phase IV study of 41 patients with RRMS, and aims to investigate the mechanism of action of cladribine on peripheral monocytes, and its impact P2X7 receptor. There was a significant reduction in monocyte count in vivo at week 1 post cladribine administration, and the subset of cells being most impacted were the CD14lo CD16+ 'non-classical' monocytes...
July 2, 2024: Clinical Immunology: the Official Journal of the Clinical Immunology Society